1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Markers

Cancer Markers

  • March 2016
  • -
  • Kalorama Information
  • -
  • 155 pages

Cancer is the number two cause of death, behind only cardiovascular disease. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. For these and other types of cancer, novel biomarkers, therapies, and diagnostic tests are being developed. Cancer Markers provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following:

Histology/Cytology:
Immunohistochemistry
In situ hybridization
Immunoassays - Tumor Markers:
Flow Cytometry
Rapid Tests:
Molecular Marker-Based

Estimates for these segments are provided for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market. This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well.

Cancer Markers provides the following data:
Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC, ISH, Immunoassays, Flow, Rapid, Molecular)
Selected International Agreements
Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH, Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP, Other Tumor Markers)
Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regions of the World
Selected Widely Used Tumor Markers
Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Response to Therapy, and Companies Developing/Marketing These Biomarkers
Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
Selected Companies Developing/Marketing Cancer Tests
Common Next Generation Molecular Test Traits
Selected Sample Preparation Reagents
Selected Cancer Test Innovations, 2015

This report contains company profiles, including coverage of the following:
Abbott Laboratories
Alere Inc. (Abbott)
bioMerieux SA
Hologic, Inc.
Illumina, Inc.
QIAGEN N.V.
Roche
Thermo Fisher Scientific, Inc.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.

Table Of Contents

Cancer Markers
ONE: EXECUTIVE SUMMARY
Market
Scope and Methodology
TWO: INTRODUCTION
Cancer Risk Assessment
Cancer Screening
Cancer Monitoring
Cancer Prognosis Assessment
Personalized Medicine/Precision Testing
Competition in Cancer Biomarkers
Molecular Markers
Precision Medicine
THREE: CANCER MARKERS MARKET ANALYSIS
FOUR: COMPANY PROFILES
20/20 GeneSystems, Inc
Abbott Laboratories
Recent Revenue History
Agreements
Abcodia Ltd.
Financings
Alere Inc. (Abbott)
Ambry Genetics Corp.
Asuragen, Inc.
Diagnostic Products
Translational/Companion Diagnostics
Agreements
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
bioMerieux SA
Recent Revenue History
Company Overview
Immunodiagnostics for Lab Professionals (Clinical Laboratories)
Molecular Diagnostics
bioTheranostics, Inc. (A bioMerieux Company)
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
Agreements
Genomic Health, Inc.
Recent Revenue History
Genoptix (A Novartis Company)
Hologic, Inc.
Recent Revenue History
Company Overview
Illumina, Inc.
Recent Revenue History
Company Overview
Myriad Genetics, Inc.
Recent Revenue History
Company Overview
QIAGEN N.V.
Recent Revenue History
Roche
Recent Revenue History
Company Overview
Roche Professional Diagnostics
Molecular Diagnostics
Tissue Diagnostics
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
Wako Pure Chemical Industries, Ltd.,


LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Figure 1-1: Cases of Cancer by Type
Figure 1-2: Cancer Marker-Based Test Market, 2015 and 2020
TWO: INTRODUCTION
Table 2-1: Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regionsnof the World
Table 2-2: Selected Widely Used Tumor Markers
Table 2-3: Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
Table 2-4: Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
Table 2-5: Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
Table 2-6: Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer,and Companies Developing/Marketing These Biomarkers
Table 2-7: Selected Biomarkers and Biomarker Panels to Predict Response to Therapy,and Companies Developing/Marketing These Biomarkers
Table 2-8: Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
Table 2-9: Selected Companies Developing/Marketing Cancer Tests
Table 2-10: Common Next Generation Molecular Test Traits
Table 2-11: Selected Sample Preparation Reagents
Table 2-12: Selected Cancer Test Innovations, 2015
THREE: CANCER MARKERS MARKET ANALYSIS
Table 3-1: Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC,ISH, Immunoassays, Flow, Rapid, Molecular)
Table 3-2: Selected International Agreements
Figure 3-1: Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH,Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP,Other Tumor Markers)




View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.